Baseline characteristics of survival and predicted survival in idiopathic pulmonary arterial hypertension patients treated withi.v. epoprostenol, oral bosentan or subcutaneous (SC) treprostinil based on the National Institute of Health Registry
| i.v. epoprostenol#,ƒ | Oral bosentan¶,## | SC treprostinil+ | i.v. epoprostenol§,¶¶ | Oral bosentan§,¶¶ | |
| Ppa mmHg | 61±13 | 57±16 | 59±13 | 59±15 | 57±15 |
| Pra mmHg | 14±6 | 10±6 | 10±5 | 10±5 | 10±5 |
| CI L·min-1·m-2 | 1.8±0.6 | 2.4±0.8 | 2.2±0.7 | 2.1±0.6 | 2.2±0.6 |
| NYHA class | |||||
| I/II | 15 (9) | 53 (16) | |||
| III | 75 (46) | 139 (82) | 262 (79) | 83 (100) | 83 (100) |
| IV | 87 (54) | 15 (9) | 17 (5) | ||
| Survival rates yrs | |||||
| 1 | 88, 59 | 96, 69 | 88, 69 | 93++ | 95++ |
| 2 | 76, 46 | 89, 57 | 80, 56 | 89++ | 87++ |
| 3 | 63, 35 | 86, 48 | 74, 46 | 78++ | 82++ |
| 4 yrs | 56, NA | NA | 69, 38 | NA | NA |
Data are presented as mean±sd, n (%). For survival rates data are presented as % observed, % predicted, unless otherwise stated. Ppa: mean pulmonary artery pressure; Pra: mean right atrial pressure; CI: cardiac index; NYHA: New York Heart Association; NA: not available. #: n = 162; ¶: n = 169; +: n = 332; §: n = 83; ƒ: from reference 14; ##: from reference 16; ¶¶: from reference 20; ++: % observed.